Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE with Lipiodol for Unresectable Gastric Cancer
NCT05361161Phase 2Not yet recruiting
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label trial of pirarubicin, oxaliplatin, raltitrexed and ethiodized oil in gastric cancer (GC). Primary endpoint: Efficacy Evaluation at 3 years. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
pirarubicinoxaliplatinraltitrexedethiodized oil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05361161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361161.